The Food and Drug Administration on Tuesday approved a once-monthly dose form of the cholesterol drug Praluent.
The drug, co-developed by Regeneron Pharmaceuticals and Sanofi, first earned FDA approval in July 2015. The new once-monthly dose of the drug allows clinicians to offer a more personalized cholesterol treatment plan for patients, according to a news release.
Praluent sits at the center of a patent dispute filed October 2014 against Regeneron and Sanofi by Amgen, which makes the rival cholesterol drug Repatha. While a district judge blocked sales of Praluent Jan. 5 after Amgen won the patent lawsuit, the U.S. Court of Appeals in February ruled the drugmakers could continue to sell the medication as they undergo the appeals process.
More articles on supply chain:
3 things to know about National Prescription Drug Take Back Day
Pharmacist lobby group: PBMs prioritize profits over medication affordability
FDA targets 14 companies advertising fake cancer products